newsfilter
← Latest News
Business Wire·

Enveric Biosciences Announces $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

ENVB
  • Enveric Biosciences (NASDAQ: ENVB) entered into definitive agreements to sell 328,802 shares of common stock at $4.41 per share via a registered direct offering priced at-the-market under Nasdaq rules.
  • The Company will concurrently issue unregistered Series G warrants to purchase up to 328,802 shares with an exercise price of $4.16, exercisable immediately & expiring five years after registration effectiveness.
  • Unregistered Series H warrants to purchase up to 328,802 shares will also be issued with an exercise price of $4.16, exercisable immediately & expiring eighteen months after registration effectiveness.
  • H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.
  • Gross proceeds are expected to be approximately $1.5 million before deducting placement agent fees & other offering expenses.
  • Net proceeds will be used for product development, working capital, & general corporate purposes.
  • The closing of the offering is expected on or about January 28, 2026, subject to customary closing conditions.
  • The common stock is offered pursuant to a Form S-3 shelf registration statement effective April 17, 2025, while the warrants are offered in a private placement under Section 4(a)(2) of the Securities Act & Regulation D.
  • Enveric is advancing neuroplastogenic small molecules including its lead candidate EB-003, which targets 5-HT 2A & 5-HT 1B receptors for potential antidepressant & anxiolytic effects.